Recent Updates
Recently added Catalysts
TLX Positive Sentiment

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

Monday, March 3, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Telix Therapeutics is hosting an investor webinar to present its late-stage and next-generation radiotherapeutic candidates focused on urologic oncology. The session will feature insights from leading experts in the field, covering developments in treatments for prostate and kidney cancers. The event is scheduled for March 11 and will last approximately 1.5 hours.
Price reaction · baseline $18.045 (2025-03-03 close) · hit after-hours · 1 other TLX headline(s) in the window, move may be shared
day 0 close · peak
-3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Showcases innovative radiotherapeutic candidates.
  • Engages global key opinion leaders in urologic oncology.
  • Provides educational insights into prostate and kidney cancers.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
7%
average across 7 past catalysts
Lead asset
131I-IPA
Phase 1 · Neoplastic Disease

Full Press Release Details

Investor webinar: Telix Therapeutics Urology Showcase and Expert Forum

Telix invites investors to join a webinar showcasing the Company’s late-stage and next-generation radiotherapeutic candidates in urologic oncology.
In this education session, Telix and global key opinion leaders will provide an overview on the development of its therapeutic candidates in prostate and kidney cancers.
EDT: Tuesday March 11, 5.30pm AEDT : Wednesday March 12, 8.30am
The event will run for approximately 1.5 hours. Rewatch the webinar here
Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute in Salt Lake City, UT
Professor of Medicine in the Department of Genitourinary Medical Oncology at MD Anderson Cancer Center in Houston, TX
Professor of Medicine at the University of Melbourne and Monash University; Founder, Chair, and Chief Medical Officer at the Melbourne Theranostic Innovation Centre in Australia

Presenters

Frequently Asked Questions

What is the focus of the Telix webinar?

The webinar focuses on Telix's late-stage and next-generation radiotherapeutic candidates in urologic oncology.

Who will present at the Telix investor webinar?

The webinar will feature global key opinion leaders and experts in urologic oncology.

When is the Telix investor webinar scheduled?

The webinar is scheduled for March 11 at 5:30 PM AEDT.

How long will the Telix webinar last?

The event will run for approximately 1.5 hours.

ShareAdd on Google
Tags: TLX Viatris Investor Conferences Healthcare Telix Therapeutics urology radiotherapeutics prostate cancer kidney cancer
Last updated: Mar 3, 2025

Biotech snapshot

Lead asset
131I-IPAPhase 1
Neoplastic Disease →

Catalyst track record

+13%
best trade around TLX's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for TLX.

See every catalyst's timing & PoA →